

file's copy

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶: A61K 9/50, 31/55		A1	(11) International Publication Number: WO 96/17598 (43) International Publication Date: 13 June 1996 (13.06.96)
(21) International Application Number: PCT/CA95/00674		(81) Designated States: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).	
(22) International Filing Date: 1 December 1995 (01.12.95)		(30) Priority Data: 270078 6 December 1994 (06.12.94) NZ	
(71)(72) Applicant and Inventor: SHERMAN, Bernard, Charles [CA/CA]; 50 Oldcolony Road, Willowdale, Ontario M2L 2K1 (CA).		Published <i>With international search report.</i>	
(74) Agent: MALCOLM JOHNSTON & ASSOCIATES; Suite 505, 133 Richmond Street West, Toronto, Ontario M5H 2L3 (CA).			

(54) Title: DILTIAZEM HYDROCHLORIDE FORMULATION

(57) Abstract

A pharmaceutical formulation containing diltiazem hydrochloride suitable for once daily oral administration comprising a blend of beads having three differing dissolution profiles.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DILTIAZEM HYDROCHLORIDE FORMULATION

FIELD OF INVENTION

A pharmaceutical formulation containing diltiazem hydrochloride suitable for once daily oral administration comprising a blend of beads having three
5 differing dissolution profiles.

BACKGROUND OF THE INVENTION

Diltiazem is a benzothiazine derivative possessing calcium antagonist activity.
10 Diltiazem blocks the influx of calcium ions in smooth and cardiac muscle and thus exerts potent cardio-vascular effects. Diltiazem has been shown to be useful in alleviating symptoms of chronic heart disease, particularly angina pectoris and myocardial ischemia and hypertension, while displaying a low incidence of side effects. The first dosage forms of diltiazem sold in the United
15 States were tablets containing 30 mg or 60 mg of diltiazem hydrochloride sold under the tradename Cardizem by Marion Laboratories Inc. Single oral doses of 30 mg and to 120 mg of Cardizem tablets result in peak plasma levels about 2 to 3 hours after ingestion, and the elimination half-life is about 3 to 5 hours. Because of the relatively rapid absorption of diltiazem hydrochloride from such
20 tablets and rapid elimination, the usual dosage regimen for immediate release tablets is for a dose to be taken three or four times daily. The need for such frequent administration may reduce patient compliance. Thus adverse therapeutic effects can arise. It thus became apparent that it would be preferable to administer diltiazem hydrochloride in a dosage form that releases
25 the diltiazem hydrochloride much more slowly than Cardizem tablets, so as to enable the frequency of ingestion by the patient to be reduced to once daily.

- 2 -

A formulation of diltiazem hydrochloride that controls the rate of release to enable once daily administration is sold in the United States under the tradename Dilacor XR by Rhone-Poulenc Rorer Pharmaceuticals Inc.

5 Dilacor XR is produced as two-piece hard gelatin capsules, with each capsule containing a plurality of tablets. The 180 mg strength of Dilacor XR contains three tablets and the 240 mg strength contains four tablets. The same tablets are used in both capsules, and each tablet contains 60 mg of diltiazem hydrochloride.

10

The tablets used in Dilacor XR are made in accordance with the invention of United States patent 4839177.

15 Each tablet is comprised of a cylindrical core containing diltiazem hydrochloride mixed with inactive ingredients which include a polymer that swells and forms a gel upon contact with aqueous fluids. Because the gel has high viscosity it swells and dissolves only very slowly in the gastrointestinal fluids to thereby retard the rate of release of the diltiazem hydrochloride. To further retard the release, insoluble polymeric platforms are affixed to the top 20 and bottom of the cylindrical core, thus leaving only the periphery exposed to the gastrointestinal fluid. The formulation of Dilacor XR capsules successfully accomplishes gradual release to enable once daily dosing, but the Dilacor XR formulation requires complex and expensive procedures to produce. In particular, production of the tablets contained in Dilacor XR capsules requires 25 production of cores containing the diltiazem hydrochloride and the affixing thereto of the insoluble platforms.

Another formulation of diltiazem hydrochloride suitable for once daily administration is now sold in the United States under the trademark Cardizem

- 3 -

CD, by Marion Laboratories Inc. Cardizem CD is sold as capsules containing a multitude of beads. The composition of the beads contained in Cardizem CD capsules is described in U.S. patent 5286497. The beads are made using core seeds to which is applied a first coating containing the diltiazem hydrochloride.

5 Over the first coating, further coatings of polymers are applied which serve to slow down and control the rate at which the diltiazem hydrochloride is released from the beads in gastrointestinal fluids.

As explained in U.S. patent 5286497, there is a particular dissolution profile 10 found to be optimum for once daily administration. This desired dissolution profile, when measured in a type 2 dissolution apparatus according to U.S. Pharmacopoeia XXII, in 0.1NHCL at 100 rpm is as follows:

- a) from 20-45% released after 6 hours
 - 15 b) from 25-50% released after 12 hours
 - c) from 35-70% released after 18 hours
 - d) not less than 70% released after 24 hours
 - e) not less than 85% released after 30 hours
- 20 The invention of U.S. patent 5286497 achieves this dissolution profile by using a mixture of beads with two differing amounts of coating.

The beads with the lesser amount of coating are referred to as "rapid release diltiazem beads" and the beads with the greater amount of coating are referred 25 to as "delayed release diltiazem beads".

It is disclosed that by making each of these types of beads so as to comply with particular dissolution requirements, the mixture of the two types of beads produces the desired dissolution profile for the final composition.

- 4 -

A difficulty with the invention of U.S. patent 5286497 is that it is difficult to reliably make the two types of beads so as to get the required dissolution profile for the final mixture.

- 5 In particular, the desired dissolution profile requires that the amount released must exceed 20% after 6 hours, but must not exceed 50% after 12 hours.

This requires that the "rapid release diltiazem beads" give a sharp step-like release of the diltiazem. Otherwise, if the amount released increases only 10 gradually with time, beads formulated to assure that at least 20% of the diltiazem is released from the final mix after 5 hours will also cause more than 50% to be released after 10 hours, thus causing the final composition to fail to meet requirements.

- 15 In view of the aforesaid problems with prior art formulations, it is an object of the invention to produce a composition of diltiazem hydrochloride suitable for once daily administration, in the form of a blend of beads that overcomes the difficulty in achieving the required dissolution profile that results from using a mixture of only two types of beads.

20

OUTLINE OF THE INVENTION

The new formulation is characterized in the following way. Beads containing diltiazem hydrochloride are made by processes the same as or similar to those 25 disclosed in U.S. patent 5286497.

However, instead of mixing only two types of beads, referred to as "rapid release beads" and "delayed release beads", three types of beads are made,

- 5 -

which will be referred to herein as "rapid release beads", "intermediate release beads", and "delayed release beads".

By using an appropriate mixture of these three types of beads, with three different amounts of coating, it is possible to obtain the desired dissolution profile for the final mix, without the need for the individual types of beads to have the sharp step-like release profile required by the invention of U.S. patent 5286497.

10

- 6 -

DETAILED DESCRIPTION OF THE INVENTION

5 The rapid release, intermediate release, and delayed release beads of the invention will typically exhibit in vitro dissolution profiles as shown in Table 1 when measured in 0.1NHCL using a type 2 apparatus at 100 rpm according to U.S. Pharmacopoeia XXII.

TABLE 1

10

	RAPID RELEASE BEADS		INTERMEDIATE RELEASE BEADS		DELAYED RELEASE BEADS	
Hours	Typical	Acceptable	Typical	Acceptable	Typical	Acceptable
15	3	70%	40% to 100%	5%	0% to 15%	3%
	6	95%	80% to 100%	17%	0% to 30%	12%
	12	100%	90% to 100%	55%	35% to 75%	25%
20	18	100%	90% to 100%	85%	65% to 95%	45%
	24	100%	95% to 100%	95%	75% to 100%	68%
25	30	100%	95% to 100%	100%	80% to 100%	90%
						70% to 100%

- 7 -

All three types of beads will usually be made by taking the same cores containing diltiazem hydrochloride and applying different amounts of polymeric coating to slow down the release. The intermediate release beads will typically have more coating than the rapid release beads, and similarly
5 the delayed released beads will typically have more coating than the intermediate release beads.

It follows that the intermediate release beads will contain a smaller percent
10 diltiazem hydrochloride by weight than the prompt release beads, and similarly the delayed release beads will contain a smaller percent diltiazem hydrochloride by weight than the intermediate release beads.

The final blend of beads will typically contain about 15% by weight rapid release beads, about 20% by weight intermediate release beads and about
15 65% by weight delayed released beads.

In view of the differences in percent diltiazem hydrochloride content as aforesaid, it follows that in the final blend, about 18% of the diltiazem hydrochloride content will be in the rapid release beads, about 20% in the
20 intermediate release beads, and about 62% in the delayed release beads.

By taking into account these percentages along with the typical dissolution data given in Table 1, it can be seen that in the final mix, the dissolution at 6 hours will be about 27%, and at 12 hours will be about 44%.

25 There is thus achieved a final mix which has dissolution over 20% at 6 hours and under 50% at 12 hours, in accordance with the objective of this invention.

- 8 -

Similarly, it can be seen that in final mix the dissolution will be under 70% at 18 hours, over 70% at 21 hours, and over 85% at 30 hours.

5 The final mix can thus be made to meet the dissolution specifications disclosed in U.S. patent 5286497 as being particularly desired to ensure uniform blood levels, these specifications being as follows:

- a) from 20% to 40% after 6 hours
- b) from 25% to 50% after 12 hours
- 10 c) from 35% to 70% after 18 hours
- d) not less than 70% after 24 hours
- e) not less than 85% after 30 hours

15 As aforesaid, all three types of beads will usually be made by first making core beads containing the diltiazem hydrochloride and then applying a polymeric coating to slow down the dissolution rate.

20 The core beads may be made by any of a number of techniques well known to persons skilled in the art of pharmaceutical formulations.

25 In one technique, the core beads are made beginning with sugar spheres having a diameter ranging from about 12 to 45 mesh and more preferably from 35 to 45 mesh. The spheres are loaded into a fluidized bed coating apparatus. In that apparatus there is sprayed onto the spheres a solution containing diltiazem hydrochloride, a polymeric binder and optionally other excipients. As the solvent is evaporated, a film containing diltiazem hydrochloride is built up to result in the core beads containing diltiazem hydrochloride.

Another technique suitable to produce core beads containing diltiazem hydrochloride is the technique known in the art as extrusion-spheronization.

In the extrusion part of this process, a mixture of diltiazem hydrochloride, 5 a binder, water and optionally other excipients is forced through a screen to product moist strands. The moist strands are then transferred to the spheronizer. In the spheronizer the strands are placed on a rotating disc where they are forced to roll outward by centrifugal force. In the process, the strands break into pieces with length approximately equal to diameter, 10 and they also become rounded as they roll. They are then dried and thus become dry core beads containing diltiazem hydrochloride.

As aforesaid, the second part of the process of producing the final beads is to apply to the core beads one or more polymeric coatings to slow down the 15 dissolution rate.

Such coating or coatings may be applied by loading the core beads into a fluidized bed coating apparatus and spraying onto the core beads a solution or suspension of suitable polymers, and other excipients in a solvent, and 20 evaporating the solvent. The solvent preferably will be water, but organic solutions also may be used.

This polymeric coating or coatings may be made using any number of polymers known in the art to be useful as slow-release coatings. Such 25 polymeric coating may be produced, for example, using polymerized acrylates or copolymers of acrylic acid and methacrylic acid or esters of either monomer (hereinafter called polymerized acrylates). These materials are available from several commercial sources.

- 10 -

Examples of such copolymers include poly (methyl methacrylate), poly (ethyl methacrylate), poly (butyl methacrylate), poly (isobutyl methacrylate), poly (isobutyl methacrylate), and poly (phenyl methacrylate).

5 The amount of polymerized acrylate contained within the polymeric coating can vary. Typically, the polymeric coating will contain from 10 to 75 w/w% of polymerized acrylate and preferably about 55-65 w/w% based on the total weight of the polymeric coating, the balance being a plasticizer and other excipients.

10 Preferred polymerized acrylates are those which are water insoluble, slightly water permeable copolymers of acrylic acid lower alkyl ester and methacrylic acid lower alkyl ester in which some ester moieties are further substituted with a tri(alkyl)ammonium group. The tri(alkyl)ammonium group is typically present in the range of about 1:30 to 1:50 relative to the amount of neutral ester present. One such preferred copolymer is a copolymer of ethyl acrylate and methyl methacrylate which contains trimethylammoniummethyl methacrylate in a range of about 1:40 relative to neutral monomers. This copolymer is commercially available from Rohm 15 Pharma GmbH under the tradename Eudragit RS. The same copolymer is available in an easy to use aqueous dispersion sold under the tradename Eudragit RS30D.

20 The polymeric coating will preferably contain a quantity of a suitable plasticizer. Examples of such plasticizers are acetyl triethyl citrate, dibutyl phthalate, tributyl citrate, triethyl citrate, acetyl triethyl citrate, propylene glycol, triacetin, polyethylene glycol and diethyl phthalate. Preferred plasticizers are triethyl citrate, tributyl citrate, and acetyl tributyl citrate.

- 11 -

The amount of plasticizer will typically be 5 to 30 w/w% based on the total weight of polymeric coating.

In addition to containing polymerized acrylate and optionally a plasticizer,
5 the polymeric coating may contain other conventional excipients including antifoaming agents such as simethicone, in the range of 0 to 2 w/w% based on the total weight of the polymeric coating. It may also contain an anti-adherent such as talc in the range of 0 to 70 w/w% and preferably 25 to 35 w/w% based on the total weight of polymeric coating.

10

A sufficient quantity of polymeric coating must be utilized to substantially envelope the core beads in order to give them the desired release (i.e. dissolution) profile. The exact quantity will depend on the composition and size of the core beads, the composition of the coating, and whether the 15 coated beads are intended to be the rapid release, intermediate release or delayed release beads. A suitable amount for each of the three types of beads can readily be determined by trial and error by persons skilled in the art. That is to say, various amounts can be applied and the dissolution profiles can be determined for the various amounts and a suitable amount 20 thereby selected to give the desired profile.

For ease of handling the beads after application of the coating to the core beads it is desirable that the dried coating not be tacky, so that the beads will not stick together. Coatings of Eudragit RS and other similar polymers 25 may be found to be excessively tacky. To solve this problem, a further coating may be applied over the tacky coating using another polymer that is not so tacky.

There are many suitable non-tacky polymers well-known in the art, including for example cellulose derivatives such as hydroxypropyl methylcellulose, which are water-soluble polymers. Another suitable nontacking polymer for such overcoat is a copolymer of methacrylic acid and methacrylic acid methyl esters sold by Rohm Pharma GmbH under the tradename Eudragit L. This polymer is insoluble in gastric fluid but soluble in neutral to weakly alkaline intestinal fluid. As with Eudragit RS, Eudragit L is available in an easy to use aqueous dispersion sold under the tradename Eudragit L30D.

10

If an overcoat is used, unless it is rapidly soluble it will further delay the dissolution of the beads, and accordingly the amount of both the primary coating and the overcoating must be selected to achieve the desired dissolution profile for each of the three types of beads.

15

In the case of the rapid release beads, a coating as aforesaid is desirable but not necessary. That is to say, the rapid release beads may take the form of the core beads without coating. Alternatively, the rapid release beads may consist of core beads coated with only a thin coating of a polymer that need not significantly delay dissolution, since there is no upper limit on the dissolution rate of the rapid release beads within the scope of the present invention.

20
25 After completion of coating and drying of the beads, the three types of beads are blended together in the required proportions for incorporation into the final dosage form.

The proportions of the three types of beads by weight will preferably be about 15% for the rapid release beads, about 20% for the intermediate

- 13 -

release beads, and about 65% for the delayed release beads. However, the percentages may differ from these preferred amounts depending on the exact dissolution profile for each of the three types of beads.

- 5 The blended diltiazem beads may be administered in a number of dosage forms known in the art. For example, they may be placed into a gelatin capsule. The blended beads may also be mixed with a binder such as microcrystalline cellulose and compressed into tablets.
- 10 The quantity of beads that are placed in each dosage unit will typically be such as to produce a dosage unit containing from 90 mg to 540 mg of diltiazem hydrochloride, and more preferably from 120 mg to 360 mg. Such a dosage unit is suitable for once daily oral ingestion for a variety of cardiovascular indications such as angina, hypertension, and arrhythmias.
- 15 As used in this application, any reference to dissolution profile should be construed as referring to the results of a dissolution test in which the amount of diltiazem hydrochloride released is measured as specified in the United States Pharmacopoeia XXII, using a type 2 apparatus at 100 rpm, a temperature of 37°C and a test solution of 0.1N HCl.
- 20 The following examples are presented to further illustrate the invention but should not be considered as limiting the invention.

- 14 -

EXAMPLE 1

5 A quantity of core beads were made by the extrusion and spheronization process containing 90% by weight diltiazem hydrochloride, on a dried basis, the balance being microcrystalline cellulose together with methylcellulose as a binder.

EXAMPLE 2

10

Rapid release beads were made by coating the core beads of example 1 with a polymeric coating using Eudragit RS30D along with plasticizer and talc. An overcoating was then applied using Eudragit L30D along with plasticizer and talc. The total amount of coating applied was such as to give finished 15 beads with the content of diltiazem hydrochloride being 77.3% by weight.

Gelatin capsules were filled with these beads, and the dissolution profile was measured and found to be as shown in table 2, the results shown being the approximate average for several capsules.

20

TABLE 2

25

Time	3 hrs.	6 hrs.	12 hrs.	18 hrs.	24 hrs.	30 hrs.
Amount released	73%	95%	100%	100%	100%	100%

- 15 -

EXAMPLE 3

Intermediate release beads were made by coating the core beads of example 2 with a polymeric coating using Eudragit RS30D along with plasticizer and talc. An overcoating was then applied using Eudragit L30D along with plasticizer and talc. The total amount of both coatings was such as to give finished beads with the content of diltiazem hydrochloride being 63.9% by weight.

10 Gelatin capsules were filled with these beads, and the dissolution profile was measured and found to be as shown in table 3, the results shown being the approximate average for several capsules.

TABLE 3

15

Time	3 hrs.	6 hrs.	12 hrs.	18 hrs.	24 hrs.	30 hrs.
Amount Released	3%	16%	54%	85%	95%	99%

20

760

- 16 -

EXAMPLE 4

Delayed release beads were made by coating the core beads of example 2
5 with a polymeric coating using Eudragit RS30D along with plasticizer and
talc. An overcoating was then applied using Eudragit L30D along with
plasticizer and talc. The amount of Eudragit RS30D used was less than that
used in making the beads of example 3, and the amount of Eudragit L30D
used was more than that used in making the beads of example 3. The total
10 amount of both coatings was such as to give finished beads with the content
of diltiazem hydrochloride being 63% by weight.

Gelatin capsules were filled with these beads, and the dissolution profile was
measured and found to be as shown in table 3, the results shown being the
15 approximate average for several capsules.

TABLE 4

20

Time	3 hrs.	6 hrs.	12 hrs.	18 hrs.	24 hrs.	30 hrs.
Amount Released	3%	12%	26%	44%	68%	88%

- 17 -

EXAMPLE 5

The beads of examples 2, 3, and 4 were mixed in the following proportion.

5

Rapid release beads from example 2	-	15%
Intermediate release beads from example 3	-	20%
Delayed release beads from example 4	-	<u>65%</u>
Total	-	100%

10

In view of the diltiazem hydrochloride percentage content contained in each of the three types of beads as stated in examples 2, 3, and 4, it will be seen that the diltiazem hydrochloride percentage content in the above mix is:

15

$$15\% \times 77.3\% + 20\% \times 63.9\% + 65\% \times 63\% = 65.3\%$$

To achieve a dose of 300 mg of diltiazem hydrochloride thus requires 300 mg/65.3% = 459mg of the mix of beads.

20

Gelatin capsules were filled each with 459mg of this mixture of beads. The dissolution profile was measured and found to be as shown in table 5, the results shown being the approximate average for several capsules.

TABLE 5

25

Time	3 hrs.	6 hrs.	12 hrs.	18 hrs.	24 hrs.	30 hrs.
Amount Released	15%	25%	42%	61%	79%	91%

WHAT IS CLAIMED:

1. A diltiazem hydrochloride formulation suitable for once daily oral administration comprising a blend of beads, such that the following dissolution profiles are satisfied when measured in a type 2 dissolution apparatus according to U.S. Pharmacopoeia XXII at 37°C at 100 rpm in 0.1N HCl:
 - 10 i) a first portion of said beads exhibit the following profile:
 - a) not less than 40% released at 3 hours
 - ii) a second portion of said beads exhibits the following profile:
 - a) not more than 30% released at 6 hours
 - b) not less than 35% released at 12 hours
 - 15 iii) a third portion of said beads exhibits the following profile:
 - a) not more than 20% released at 6 hours
 - b) not more than 35% released at 12 hours
 - c) not less than 50% released at 24 hours
 - 20 iv) the blend exhibits the following profile:
 - a) from 20% to 45% released after 6 hours
 - b) from 25% to 50% released after 12 hours
 - c) from 35% to 70% released after 18 hours

- 19 -

- d) not less than 70% released after 24 hours
 - e) not less than 85% released after 30 hours
2. A formulation as in claim 1 wherein said beads are comprised of
5 cores containing diltiazem hydrochloride in association with
pharmaceutically acceptable excipients and a polymeric coating which
envelopes said cores.
3. A formulation as in claim 1 or 2 wherein said first portion of beads
10 constitutes from 5% to 25% of the totality of beads by weight, said
second portion of beads constitutes from 10% to 30% of the totality
of beads by weight, and said third portion of beads constitutes from
50% to 75% of the totality of beads by weight.
- 15 4. A formulation as in claim 2 or 3 wherein the polymeric coating on
some or all of the beads contains polymerized acrylate and a
plasticizer.
5. The formulation of any of claims 1 to 4 contained within a gelatin
20 capsule.

INTERNATIONAL SEARCH REPORT

Internat'l Application No
PCT/CA 95/00674A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/50 A61K31/55

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US-A-5 286 497 (DENNIS L. HENDRICKSON) 15 February 1994 cited in the application see column 1, line 1 - column 3, line 33; claims 1-13 ---	1-5
Y	EP-A-0 320 097 (ELAN CORPORATION PLC) 14 June 1989 see page 2 - page 6 ---	1-5
Y	EP-A-0 386 967 (YAMANOUCHI PHARMACEUTICAL CO. LTD) 12 September 1990 see page 2 - page 4; example 3 ---	1-5
Y	DE-A-39 22 167 (SCHWARZ PHARMA AG) 17 January 1991 see claims 1-18 ---	1-5
		-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

1

Date of the actual completion of the international search

13 February 1996

Date of mailing of the international search report

12.03.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentdaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Tzschoppe, O

INTERNATIONAL SEARCH REPORTIntern. Application No
PCT/CA 95/00674**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US-A-3 247 066 (GEORGE MILOSOVICH ET AL.) 19 April 1966 see column 2, line 48 - column 7, line 42 see column 12, line 1 - line 6 -----	1-5
I		

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No

PCT/CA 95/00674

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5286497	15-02-94	US-A- 5439689 US-A- 5470584 AU-B- 653223 AU-B- 1632692 CA-A- 2068980 EP-A- 0514814 JP-A- 5178747 NZ-A- 242730	08-08-95 28-11-95 22-09-94 26-11-92 21-11-92 25-11-92 20-07-93 27-09-94
EP-A-320097	14-06-89	AU-B- 2377588 AU-B- 7943591 JP-A- 1132521 JP-B- 7116044 US-A- 5002776 AU-B- 634660 US-A- 5336504 US-A- 5219621	08-06-89 12-09-91 25-05-89 13-12-95 26-03-91 25-02-93 09-08-94 15-06-93
EP-A-386967	12-09-90	AT-T- 124864 AU-B- 623233 AU-B- 5122790 CA-A- 2011919 CN-A- 1045524 DE-D- 69020758 DE-T- 69020758 FI-A- 951606 JP-A- 3007238 US-A- 5028664 US-A- 5258186	15-07-95 07-05-92 13-09-90 10-09-90 26-09-90 17-08-95 07-12-95 05-04-95 14-01-91 02-07-91 02-11-93
DE-A-3922167	17-01-91	DE-A- 3812799 EP-A, B 0338383 ES-T- 2054918 JP-A- 2022222 US-A- 5472710	26-10-89 25-10-89 16-08-94 25-01-90 05-12-95
US-A-3247066	19-04-66	BE-A- 676524 DE-A- 1617724 FR-A- 1594514 GB-A- 1085739	18-07-66 30-03-72 08-06-70